Search Result

Results for "

metabolic-dysfunction-associated steatohepatitis

" in MedChemExpress (MCE) Product Catalog:

標的別:	17β-HSD (5) Acetyl-CoA Carboxylase (1) ACSL Family (1) AMPK (2) Amylases (1) Angiotensin-converting Enzyme (ACE) (1) ASK1 (1) ATP Citrate Lyase (3) Bacterial (1) Cyclophilin (1) Dipeptidyl Peptidase (1) Drug Derivative (1) Endogenous Metabolite (1) FABP (2) FAP (1) FGFR (1) FXR (7) G protein-coupled Bile Acid Receptor 1 (1) GABA Receptor (2) GLUT (1) Glycosidase (1) GPR119 (1) Heme Oxygenase (HO) (1) Interleukin Related (2) Keap1-Nrf2 (2) LDLR (1) Lipase (1) Mitochondrial Metabolism (2) Mitophagy (1) NF-κB (1) NOD-like Receptor (NLR) (1) P2Y Receptor (1) p38 MAPK (2) PPAR (5) PROTACs (1) Pyroptosis (1) Quinone Reductase (1) Reactive Oxygen Species (ROS) (1) SARS-CoV (1) Small Interfering RNA (siRNA) (2) Thyroid Hormone Receptor (4) TNF Receptor (1)
研究分野別:	Cancer (1) Cardiovascular Disease (1) Infection (3) Inflammation/Immunology (20) Metabolic Disease (23)
Oligonucleotides:	siRNA drugs (1) siRNAs (2)

阻害剤およびアゴニスト

ペプチド

阻害性抗体

天然物

オリゴヌクレオチド

製品番号	製品名	Target	研究分野	構造式

HY-172317

AZD2389	FAP	Metabolic Disease
AZD2389 is a potent and orally active FAP inhibitor. AZD2389 can be used for the study of metabolic dysfunction-associated steatohepatitis .

HY-P990964

Efimosfermin alfa BOS-580; LLF580	FGFR	Metabolic Disease Inflammation/Immunology
Efimosfermin alfa is a genetically engineered FGF21 variant. Efimosfermin alfa exerts its function by activating the FGFR1c/β-Klotho complex. Efimosfermin alfa is applicable to researches on metabolic dysfunction-associated steatohepatitis, obesity and mild hypertriglyceridemia .

HY-160929

Linafexor CS-0159	FXR	Inflammation/Immunology
Linafexor (CS-0159) is a FXR agonist and bile acid homeostasis modulator. Linafexor exerts its effects by activating FXR, a regulator of liver function. Linafexor is applicable to research related to primary sclerosing cholangitis (PSC). Linafexor is also suitable for research in the field of metabolic dysfunction-associated steatohepatitis (MASH) .

HY-N8599

Cichoriin 2 Publications Verification	Amylases Glycosidase Lipase Dipeptidyl Peptidase p38 MAPK PPAR P2Y Receptor NOD-like Receptor (NLR) SARS-CoV Pyroptosis GLUT Angiotensin-converting Enzyme (ACE) NF-κB	Infection Metabolic Disease Inflammation/Immunology
Cichoriin is an orally active coumarin glycoside with broad biological activities. Cichoriin exhibits inhibitory activities against α-amylase, α-glucosidase, pancreatic lipase and DPP-IV, with IC₅₀ values of 5.76, 2.94, 16.83 and 9.16 μg/mL, respectively. Cichoriin significantly improves metabolic dysfunction-associated steatohepatitis (MASH) in mice by activating the AMPK signaling pathway. Cichoriin upregulates PPAR-γ in adipose tissue and alleviates obesity and associated cardiorenal injury in rats. Cichoriin blocks monosodium urate crystal-induced activation of the NLRP3 inflammasome and cell pyroptosis by inhibiting P2Y₁₄R (IC₅₀ = 8.47 nM). In silico virtual screening reveals that Cichoriin has a strong binding affinity for SARS-CoV-2 .

HY-158766

3-sucCA 3-Succinylated cholic acid	Endogenous Metabolite Bacterial	Infection Inflammation/Immunology
3-sucCA is an orally available bacterial bile acid that exerts anti-MASH effects by promoting the growth of Akkermansia muciniphila. By remodeling the intestinal microbiota and promoting the growth of Akkermansia, 3-sucCA can improve intestinal barrier damage and reduce chronic low-level inflammation, thereby alleviating the progression of metabolic dysfunction-associated steatohepatitis (MASH). 3-sucCA accelerates the synthesis of cell wall peptidoglycan and has in vivo efficacy in the mouse MAFL-MASH model. 3-sucCA levels are low in the MAFLD model and are mainly used in the study of MASH .

HY-177704

ACSL5-IN-1	ACSL Family Drug Derivative	Metabolic Disease Cancer
ACSL5-IN-1 (Compound A) is an ACSL5 inhibitor with body weight-reducing activity. ACSL5-IN-1 inhibits ACSL5, an enzyme linked to fatty acid metabolism. ACSL5-IN-1 reduces body weight in diet-induced obesity mice. ACSL5-IN-1 can be used for the research of obesity, metabolic dysfunction-associated steatohepatitis, metabolic syndrome, non-alcoholic fatty liver disease, type 2 diabetes, acute myeloid leukemia, colorectal cancer, and breast cancer .

HY-171454

DA-1241	GPR119	Metabolic Disease Inflammation/Immunology
DA-1241 is a GPR119 agonist. DA-1241 reduces macrophage differentiation through downregulation of NFκB signaling by activating GPR119. DA-1241, alone and in combination with a DPP4 inhibitor, reduces liver inflammation and restores inflammation-related liver gene expression. DA-1241 can be used for the research of metabolic dysfunction-associated steatohepatitis (MASH) .

HY-164221A

Rapirosiran sodium ALN-HSD sodium	Small Interfering RNA (siRNA) 17β-HSD	Inflammation/Immunology
Rapirosiran (ALN-HSD) sodium is a *HSD17β13-targeting siRNA. Rapirosiran sodium can be used for the research of metabolic dysfunction-associated* steatohepatitis .

HY-P11208C

mNLS-CPP-WSTF TFA	GABA Receptor	Inflammation/Immunology
mNLS-CPP-WSTF TFA is the trifluoroacetate salt of mNLS-CPP-WSTF (HY-P11208). mNLS-CPP-WSTF is a nuclear localization signal (NLS)-cell-penetrating peptide based on the mouse WSTF sequence. mNLS-CPP-WSTF significantly inhibits the GABARAP-WSTF interaction, WSTF degradation and inflammatory gene expression. mNLS-CPP-WSTF effectively attenuates chronic inflammation, liver fibrosis and cartilage damage in metabolic-dysfunction-associated steatohepatitis (MASH) and osteoarthritis (OA) mice model. mNLS-CPP-WSTF is promising for research of chronic inflammatory diseases such as MASH and OA .

HY-156065

S217879	Keap1-Nrf2 Reactive Oxygen Species (ROS) Interleukin Related	Metabolic Disease
S217879 is an orally active and selective NRF2 activator. S217879 activates the NRF2 pathway by specifically disrupting the KEAP1 (K_d: 4.15 nM)-NRF2 interaction, and upregulates the antioxidant response. S217879 also ameliorates steatohepatitis and reduces the degree of liver fibrosis. S217879 can be used in the research of metabolic dysfunction-associated steatotic liver disease and nonalcoholic steatohepatitis .

HY-172661

Kylo-0603	Thyroid Hormone Receptor Interleukin Related LDLR	Infection Metabolic Disease
KYLO-0603 is an orally active, selective THR-β agonist (EC₅₀ : 31.07 nM). KYLO-0603 has significant activity in lowering serum cholesterol and low-density lipoprotein cholesterol. KYLO-0603 upregulates the expression of THR-regulated genes (including iodothyronine deiodinase 1 (Dio1), malic enzyme 1 (Me1), and thyroid hormone response (Thrsp) gene) and inhibits the expression of inflammatory and fibrotic genes (low-density lipoprotein receptor (LDL-R) gene) by activating THR-β receptors. KYLO-0603 can be used to treat metabolic dysfunction-associated steatohepatitis (MASH) and liver fibrosis research .

HY-P11208

mNLS-CPP-WSTF	GABA Receptor	Inflammation/Immunology
mNLS-CPP-WSTF is a nuclear localization signal (NLS)-cell-penetrating peptide based on the mouse WSTF sequence. mNLS-CPP-WSTF significantly inhibits the GABARAP-WSTF interaction, WSTF degradation and inflammatory gene expression. mNLS-CPP-WSTF effectively attenuates chronic inflammation, liver fibrosis and cartilage damage in metabolic-dysfunction-associated steatohepatitis (MASH) and osteoarthritis (OA) mice model. mNLS-CPP-WSTF is promising for research of chronic inflammatory diseases such as MASH and OA .

HY-164221

Rapirosiran ALN-HSD; ALN-288996; AD-288996	17β-HSD Small Interfering RNA (siRNA)	Inflammation/Immunology
Rapirosiran (ALN-HSD) is a *HSD17β13-targeting siRNA. Rapirosiran can be used for the research of metabolic dysfunction-associated* steatohepatitis .

HY-178015

THR-β agonist 11	Thyroid Hormone Receptor	Metabolic Disease Inflammation/Immunology
THR-β agonist 11 is an orally active and selective thyroid hormone receptor (THR-β) agonist. THR-β agonist 11 shows potent cholesterol-lowering activity in cholesterol-fed rats. THR-β agonist 11 significantly reduces serum total TG, LDL-cholesterol, liver total TC and TG levels, and alleviates hepatic steatosis, inflammation and fibrosis in HFD-CCl4-induced Metabolic dysfunction-associated steatohepatitis (MASH) model mice. THR-β agonist 11 can be used for the study of metabolic dysfunction-associated steatohepatitis (MASH) and other fibrotic diseases .

HY-170369

SHO1122147	Mitochondrial Metabolism	Metabolic Disease
SHO1122147 (Compound 7m) affects the mitochondrial electron transport chain, exhibits mitochondrial uncoupling activity (EC₅₀=3.6 μM), and increases the oxygen consumption rate (OCR=69%) and promotes cellular respiration. SHO1122147 is orally active, and can be used in reaearch of obesity and metabolic dysfunction-associated steatohepatitis (MASH) .

HY-175676

THR-β agonist 10	Thyroid Hormone Receptor	Metabolic Disease Inflammation/Immunology
THR-β agonist 10 is an orally active and selective THR-β agonist, with an EC₅₀ of 11 nM. THR-β agonist 10 significantly reduces ALT (Alanine Aminotransferase), TC (Total Cholesterol), and LDL-C (Low-Density Lipoprotein Cholesterol) levels, and improves steatosis, ballooning, inflammation and fibrosis in the metabolic dysfunction-associated steatohepatitis (MASH) mouse model. THR-β agonist 10 can be used for the study of MASH .

HY-174887

THR-β agonist 9	Thyroid Hormone Receptor AMPK Acetyl-CoA Carboxylase Mitochondrial Metabolism	Metabolic Disease
THR-β agonist 9 is a potent, selective, and His435 mutation-sensitive THR-β (EC₅₀: 3.2 nM) agonist. THR-β agonist 9 has moderate selectivity (approximately 10-fold) and good activation capacity (EC₅₀: 134.2 nM to 515.5 nM) for multiple His435 mutants (H435A, H435Y, and H435R). THR-β agonist 9 has the potential to be used in the study of dyslipidemia, metabolic dysfunction-associated steatohepatitis (MASH), or resistance to thyroid hormone (RTH) .

HY-174858

dASK1-VHL	PROTACs ASK1 p38 MAPK	Metabolic Disease
dASK1-VHL is an orally active PROTAC degrader targeting ASK1. dASK1-VHL can effectively bind VHL and promote the selective degradation of ASK1. dASK1-VHL effectively reduces ASK1 protein levels, inhibits the activation of p38 MAPK, and reduces liver lipid content. dASK1-VHL provides new ideas for the study of Metabolic dysfunction-associated steatohepatitis (MASH) (Pink: ASK1 ligand 1 (HY-174860); Blue: E3 ligand (S,R,S)-AHPC (HY-125845); Black: Linker, (S,R,S)-AHPC-CO-C2-PEG-NHCO-C2-COOH (HY-174861) .

HY-173265

CypB-IN-1	Cyclophilin	Metabolic Disease Inflammation/Immunology
CypB-IN-1 (Compound 11) is an inhibitor of cyclophilin B (cyclophilin B) with a K_d value of 12 nM. CypB-IN-1 can be applied to the research field of metabolic dysfunction-associated steatohepatitis (MASH) and the liver fibrosis diseases resulting from it .

HY-159881

SHS206	Mitophagy	Metabolic Disease
SHS206 (compound 6n) is an orally active mitochondrial uncoupler that reduces hepatic triglyceride levels. SHS206 exhibits in vivo efficacy in the GAN mouse model and shows inhibitory effects on metabolic dysfunction-associated steatohepatitis (MASH) .

HY-168629

FXR agonist 9	FXR	Metabolic Disease
FXR agonist 9 (compound 26) is an oral active and selectivity FXR partial agonist with the EC₅₀ of 0.09 µM (75.13 % maximum efficacy). FXR agonist 9 ameliorates pathological features in HFD and CCl₄(HY-Y0298)-induced metabolic dysfunction-associated steatohepatitis mice .

HY-172122

FXR/HSD17B13 modulator 1	FXR 17β-HSD	Metabolic Disease
FXR/HSD17B13 modulator 1 (compound 6) is a potent modulator of FXR/HSD17B13. FXR/HSD17B13 modulator 1 plays an important roel in metabolic dysfunction-associated steatohepatitis (MASH) research .

HY-168713

LZ-007	FXR	Metabolic Disease
LZ-007 is an agonist for farnesoid X receptor (FXR) with an EC₅₀ of 51 nM measuring by TR-FRET assay, or an EC₅₀ of 76 nM in HepG2 cell. LZ-007 exhibits good pharmacokinetic characheristics in SD rats. LZ-007 ameliorates western diet and CCl4 (HY-Y0298)-induced mice metabolic dysfunction-associated steatohepatitis

HY-172883

ABP/PPAR modulator 1	FABP PPAR	Metabolic Disease Inflammation/Immunology
ABP/PPAR modulator 1 is an orally active FABP and PPAR multiple modulator (IC₅₀s of 0.65  μM and 1.08  μM for FABP1 and FABP4, EC₅₀s of 9.19  μM, 2.20  μM and 1.58 μM for PPARα, PPARγ and PPARδ). ABP/PPAR modulator 1 has potent anti-metabolic dysfunction-associated steatohepatitis (MASH) activity. ABP/PPAR modulator 1 dose-dependently ameliorates multiple pathological characteristics of fatty liver in WD + Carbon tetrachloride-induced MASH mice model .

HY-174133

HSD17B13-IN-104	17β-HSD	Metabolic Disease Inflammation/Immunology
HSD17B13-IN-104 (Compound 32) is an orally active, highly potent and selective HSD17B13 inhibitor (IC₅₀=2.5 nM). HSD17B13-IN-104 regulates hepatic lipid metabolism by inhibiting the SREBP-1c/FAS pathway. HSD17B13-IN-104 blocks HSD17B13 enzymatic activity to improve hepatic lipid accumulation. HSD17B13-IN-104 is promising for research of metabolic dysfunction-associated steatohepatitis .

HY-172883A

(E/Z)-ABP/PPAR modulator 1	FABP PPAR	Metabolic Disease Inflammation/Immunology
(E/Z)-ABP/PPAR modulator 1 is a mixture of the E and Z isomers of ABP/PPAR modulator 1 (HY-172883). ABP/PPAR modulator 1 is an orally active FABP and PPAR multiple modulator (IC₅₀s of 0.65  μM and 1.08  μM for FABP1 and FABP4, EC₅₀s of 9.19  μM, 2.20  μM and 1.58 μM for PPARα, PPARγ and PPARδ). ABP/PPAR modulator 1 has potent anti-metabolic dysfunction-associated steatohepatitis (MASH) activity. ABP/PPAR modulator 1 dose-dependently ameliorates multiple pathological characteristics of fatty liver in WD + Carbon tetrachloride-induced MASH mice model .

HY-179591

BGT-002 326E	ATP Citrate Lyase PPAR	Metabolic Disease
BGT-002 (326E) is an orally active dual ACLY inhibitor and PPARα agonist. BGT-002 reduces lipogenesis by inhibiting synthesis and promoting efflux. BGT-002 demonstrates efficacy in ameliorating metabolic dysfunction-associated steatohepatitis (MASH) and improving hyperlipidemia in vivo. BGT-002 can be used for hypercholesterolemia and MASH research .

HY-182750

ACLY-IN-3	ATP Citrate Lyase	Inflammation/Immunology
ACLY-IN-3 is an ATP-citrate lyase (ACLY) inhibitor with an IC₅₀ of 0.036 μM and a target K_d of 0.54 μM. ACLY-IN-3 interacts with the allosteric binding site of ACLY to inhibit its activity. ACLY-IN-3 exhibits excellent lipid-lowering effects and alleviates hepatic inflammation and liver fibrosis. ACLY-IN-3 can be used for the research of metabolic dysfunction-associated steatohepatitis .

HY-183279

FXR antagonist 4	FXR AMPK	Metabolic Disease
FXR antagonist 4 (Compound 4l) is an orally active, selective FXR antagonist with an IC₅₀ of 0.70 μM. FXR antagonist 4 binds to FXR, differentially regulates bile acid and lipid transporter genes, and exerts no effect on gluconeogenesis-related genes. FXR modulator 1 activates the AMPK signaling pathway to inhibit fatty acid synthesis. FXR modulator 1 alleviates hepatic steatosis, ballooning degeneration and fibrosis, and improves dyslipidemia. FXR modulator 1 can be used for research on metabolic dysfunction-associated steatohepatitis .

HY-182751

ACLY-IN-4	ATP Citrate Lyase	Inflammation/Immunology
ACLY-IN-4 is an ATP-citrate lyase (ACLY) inhibitor with an IC₅₀ of 0.022 μM and a K_d of 0.19 μM. ACLY-IN-4 binds to the allosteric binding site of ACLY. ACLY-IN-4 exhibits hypolipidemic, anti-steatotic, insulin sensitivity-improving, anti-oxidative stress, anti-inflammatory and anti-fibrotic activities. ACLY-IN-4 alleviates hepatic steatosis, systemic insulin resistance, oxidative stress, hepatic inflammation and fibrosis. ACLY-IN-4 can be used for the research of metabolic dysfunction-associated steatohepatitis .

HY-183318

PPARα/δ agonist 4	PPAR	Metabolic Disease
PPARα/δ agonist 4 is a potent orally active and selective dual peroxisome proliferator-activated receptor (PPAR) α/δ agonist with EC₅₀s of 0.36 and 1.31 nM, respectively. PPARα/δ agonist 4 exhibits >123-fold selectivity over PPARγ (EC₅₀ = 160.84 nM). PPARα/δ agonist 4 upregulates expression of downstream fatty acid oxidation genes PDK4, CPT1A, and ACADVL. PPARα/δ agonist 4 can be used for the research of metabolic dysfunction-associated steatohepatitis .

HY-183692

FXR agonist 18	FXR G protein-coupled Bile Acid Receptor 1 TNF Receptor Heme Oxygenase (HO) Quinone Reductase Keap1-Nrf2	Cardiovascular Disease Inflammation/Immunology
FXR agonist 18 is an orally active FXR agonist, with an EC₅₀ of 10 nM against human FXR and an EC₅₀ of 1360 nM against human TGR5. FXR agonist 18 inhibits inflammatory responses by reducing nitrite production, downregulating the expression of pro-inflammatory genes (Tnf, Adgre1, Cyp8b1, upregulating the expression of FXR, Hmox1, Nqo1, Nrf2, and enhancing antioxidant responses. FXR agonist 18 ameliorates liver fibrosis in mice, exhibits protective effects in mice with cholestatic liver injury, and shows anti-MASH efficacy. FXR agonist 18 can be used in studies of metabolic dysfunction-associated steatohepatitis .

HY-183309

FXR/HSD17B13-modulator-2	FXR 17β-HSD	Inflammation/Immunology
FXR/HSD17B13-modulator-2 is a dual FXR activator and HSD17B13 inhibitor with human FXR EC₅₀ of 128 nM, human HSD17B13 IC₅₀ of 0.18 μM, high selectivity over related nuclear receptors and HSD17B isoforms, and oral effectiveness.FXR/HSD17B13-modulator-2 alleviates fatty liver, regulates lipid metabolism, reduces inflammation, and attenuates hepatic fibrosis.FXR/HSD17B13-modulator-2 is the first non-carboxylic acid dual FXR/HSD17B13 modulator.FXR/HSD17B13-modulator-2 can be used for the research of metabolic dysfunction-associated steatohepatitis .

製品番号	製品名	Target	研究分野

HY-P11208C

mNLS-CPP-WSTF TFA	GABA Receptor	Inflammation/Immunology
mNLS-CPP-WSTF TFA is the trifluoroacetate salt of mNLS-CPP-WSTF (HY-P11208). mNLS-CPP-WSTF is a nuclear localization signal (NLS)-cell-penetrating peptide based on the mouse WSTF sequence. mNLS-CPP-WSTF significantly inhibits the GABARAP-WSTF interaction, WSTF degradation and inflammatory gene expression. mNLS-CPP-WSTF effectively attenuates chronic inflammation, liver fibrosis and cartilage damage in metabolic-dysfunction-associated steatohepatitis (MASH) and osteoarthritis (OA) mice model. mNLS-CPP-WSTF is promising for research of chronic inflammatory diseases such as MASH and OA .

HY-P11208

mNLS-CPP-WSTF	GABA Receptor	Inflammation/Immunology
mNLS-CPP-WSTF is a nuclear localization signal (NLS)-cell-penetrating peptide based on the mouse WSTF sequence. mNLS-CPP-WSTF significantly inhibits the GABARAP-WSTF interaction, WSTF degradation and inflammatory gene expression. mNLS-CPP-WSTF effectively attenuates chronic inflammation, liver fibrosis and cartilage damage in metabolic-dysfunction-associated steatohepatitis (MASH) and osteoarthritis (OA) mice model. mNLS-CPP-WSTF is promising for research of chronic inflammatory diseases such as MASH and OA .

HY-P11207

NLS-CPP NLS-cell penetrating peptide	ペプチド	Inflammation/Immunology
NLS-CPP is a nuclear localization signal (NLS)-cell-penetrating peptide, which contains the NLS of OCT6. NLS-CPP facilitates nuclear delivery. NLS-CPP can be used for chronic inflammatory diseases s research, such as metabolic-dysfunction-associated steatohepatitis (MASH) and osteoarthritis (OA) .

製品番号	製品名	Target	研究分野	Image

HY-P990964

Efimosfermin alfa BOS-580; LLF580	FGFR	Metabolic Disease Inflammation/Immunology
Efimosfermin alfa is a genetically engineered FGF21 variant. Efimosfermin alfa exerts its function by activating the FGFR1c/β-Klotho complex. Efimosfermin alfa is applicable to researches on metabolic dysfunction-associated steatohepatitis, obesity and mild hypertriglyceridemia .

Cichoriin 2 Publications Verification	Infection Structural Classification Monophenols other families Classification of Application Fields Coumarins Phenols Phenylpropanoids Plants Disease Research Fields Source Classification	Amylases Glycosidase Lipase Dipeptidyl Peptidase p38 MAPK PPAR P2Y Receptor NOD-like Receptor (NLR) SARS-CoV Pyroptosis GLUT Angiotensin-converting Enzyme (ACE) NF-κB
Cichoriin is an orally active coumarin glycoside with broad biological activities. Cichoriin exhibits inhibitory activities against α-amylase, α-glucosidase, pancreatic lipase and DPP-IV, with IC₅₀ values of 5.76, 2.94, 16.83 and 9.16 μg/mL, respectively. Cichoriin significantly improves metabolic dysfunction-associated steatohepatitis (MASH) in mice by activating the AMPK signaling pathway. Cichoriin upregulates PPAR-γ in adipose tissue and alleviates obesity and associated cardiorenal injury in rats. Cichoriin blocks monosodium urate crystal-induced activation of the NLRP3 inflammasome and cell pyroptosis by inhibiting P2Y₁₄R (IC₅₀ = 8.47 nM). In silico virtual screening reveals that Cichoriin has a strong binding affinity for SARS-CoV-2 .

製品番号	製品名		Classification

HY-164221A

Rapirosiran sodium ALN-HSD sodium		siRNAs siRNA drugs
Rapirosiran (ALN-HSD) sodium is a *HSD17β13-targeting siRNA. Rapirosiran sodium can be used for the research of metabolic dysfunction-associated* steatohepatitis .

HY-164221

Rapirosiran ALN-HSD; ALN-288996; AD-288996		siRNAs
Rapirosiran (ALN-HSD) is a *HSD17β13-targeting siRNA. Rapirosiran can be used for the research of metabolic dysfunction-associated* steatohepatitis .

オンラインお問い合わせ

入力情報は安全に管理されます. ※ 必須入力項目.

日本の代理先をお選びくださいナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
タイトル			国或いは地域 *
お名前 *			組纖名 *
デパートメント *
メールアドレス *			製品名 *
製品番号			カスタマ需要量 *
電話番号 *
必ず会社名を記載ください。個人への返信は行いません。
備考

バルクお問い合わせ

Inquiry Information

製品名:
製品番号:
数量:
MCE 日本正規代理店: